Transgenic mice that express Cre recombinase under control of a skeletal muscle-specific promoter from mef2c

Genesis (United States)

Volumn 42, Issue 1, 2005, Pages 28-32

  Heidt, Analeah B ^a   Black, Brian L ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cre recombinase; MEF2C; ROSA26R; Skeletal muscle; Transgenic mouse

Indexed keywords

CRE RECOMBINASE;

ANIMAL TISSUE; ARTICLE; CELL REGENERATION; CONTROL SYSTEM; CONTROLLED STUDY; ENHANCER REGION; GENE; GENE CONTROL; GENE FUNCTION; GENE INACTIVATION; IMMUNOHISTOCHEMISTRY; MALE; MEF2C GENE; MOLECULAR CLONING; MOUSE; MUSCLE CELL; MUSCLE DEVELOPMENT; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; SKELETAL MUSCLE; TRANSGENIC MOUSE;

MUS MUSCULUS;

EID: 20044377250     PISSN: 1526954X     EISSN: None     Source Type: Journal    
DOI: 10.1002/gene.20123     Document Type: Article

References (22)

1. Amacher SL, Buskin JN, Hauschka SD. 1993. Multiple regulatory elements contribute differentially to muscle creatine kinase enhancer activity in skeletal and cardiac muscle. Mol Cell Biol 13:2753-2764.
2. Anderson JP, Dodou E, Heidt AB, De Val SJ, Jaehnig EJ, Greene SB, Olson EN, Black BL. 2004. HRC is a direct transcriptional target of MEF2 during cardiac, skeletal, and arterial smooth muscle development in vivo. Mol Cell Biol 24:3757-3768.
3. Bi W, Drake CJ, Schwarz JJ. 1999. The transcription factor MEF2C-null mouse exhibits complex vascular malformations and reduced cardiac expression of angiopoietin 1 and VEGF. Dev Biol 211:255-207.
4. Black BL, Olson EN, 1998. Transcriptional control of muscle development by myocyte enhancer factor-2 (MEF2) proteins. Annu Rev Cell Dev Biol 14:107-196.
5. Bothe GW, Haspel JA, Smith CL, Wiener HH, Burden SJ. 2000. Selective expression of Cre recombinase in skeletal muscle fibers. genesis 26:165-166.
6. Dodou E, Xu SM, Black BL. 2003. mef2c is activated directly by myogenic basic helix-loop-helix proteins during skeletal muscle development in vivo. Mech Dev 120:1021-1032.
7. Edmondson DG, Lyons GE, Martin JF, Olson EN. 1994. Mef2 gene expression marks the cardiac and skeletal muscle lineages during mouse embryogenesis. Development 120:1251-1263.
8. Ferrari S, Molinari S, Melchionna R, Cusella-De Angelis MG, Battini R, De Angelis L, Kelly R, Cossu G. 1997. Absence of MEF2 binding to the A/T-rich element in the muscle creatine kinase (MCK) enhancer correlates with lack of early expression of the MCK gene in embryonic mammalian muscle. Cell Growth Differ 8: 23-34.
9. Gossett LA, Kelvin DJ, Sternberg EA, Olson EN. 1989. A new myocytespecinc enhancer-binding factor that recognizes a conserved element associated with multiple muscle-specific genes. Mol Cell Biol 9:5022-5033.
10. Hevener AL, He W, Barak Y, Le J, Bandyopadhyay G, Olson P, Wilkes J, Evans RM, Olefsky J. 2003. Muscle-specific Pparγ deletion causes insulin resistance. Nat Med 9:1491-1497.
11. Jiang P, Song J, Gu G, Slonimsky E, Li E, Rosenthal N. 2002. Targeted deletion of the MLC1f/3f downstream enhancer results in precocious MLC expression and mesoderm ablation. Dev Biol 243:281-293.
12. Lin Q, Schwarz J, Bucana C, Olson EN. 1997. Control of mouse cardiac morphogenesis and myogenesis by transcription factor MEF2C. Science 276:1404-1407.
13. Lin Q, Lu J, Yanagisawa H, Webb R, Lyons GE, Richardson JA, Olson EN. 1998. Requirement of the MADS-box transcription factor MEF2C for vascular development. Development 125: 4565-4574.
14. McGrew MJ, Bogdanova N, Hasegawa K, Hughes SH, Kitsis RN, Rosenthal N. 1996. Distinct gene expression patterns in skeletal and cardiac muscle are dependent on common regulatory sequences in the MLC1/3 locus. Mol Cell Biol 16:4524-4534.
15. Miwa T, Koyama T, Shirai M. 2000. Muscle specific expression of Cre recombinase under two actin promoters in transgenic mice, genesis 26:136-138.
16. Musaro A, McCullagh KJ, Naya FJ, Olson EN, Rosenthal N. 1999. IGF-1 induces skeletal myocyte hypertrophy through calcineurin in association with GATA-2 and NF-ATc1. Nature 400: 581-585.
17. Norris AW, Chen L, Fisher SJ, Szanto I, Ristow M, Jozsi AC, Hirshman MF, Rosen ED, Goodyear LJ, Gonzalez FJ, Spiegelman BM, Kahn CR. 2003. Muscle-specific PPARgamma-deficient mice develop increased adiposity and insulin resistance but respond to thiazolidinediones. J Clin Invest 112:608-618.
18. Rao MV, Donoghue MJ, Merlie JP, Sanes JR. 1996. Distinct regulatory elements control muscle-specific, fiber-type-selective, and axially graded expression of a myosin light-chain gene in transgenic mice. Mol Cell Biol 16:3909-3922.
19. Soriano P. 1999. Generalized lacZ expression with the ROSA26 Cre reporter strain. Nat Genet 21:70-71.
20. Tsai FY, Keller G, Kuo FC, Weiss M, Chen J, Rosenblatt M, Alt FW, Orkin SH. 1994. An early haematopoietic defect in mice lacking the transcription factor GATA-2. Nature 371:221-226.
21. Wang J, Wilhelmsson H, Graff C, Li H, Oldfors A, Rustin P, Bruning JC, Kahn CR, Clayton DA, Barsh GS, Thoren P, Larsson NG. 1999. Dilated cardiomyopathy and atrioventricular conduction blocks induced by heart-specific inactivation of mitochondrial DMA gene expression. Nat Genet 21:133-137.
22. Wang DZ, Valdez MR, McAnally J, Richardson J, Olson EN. 2001. The Mef2c gene is a direct transcriptional target of myogenic bHLH and MEF2 proteins during skeletal muscle development. Development 128:4623-4633.